Commissioner Jozef Síkela delivered a speech at the inaugural HERA Industry Days, outlining a strategic push under the EU's Global Gateway initiative to enhance health security through partnerships in Africa and Latin America and the Caribbean (LAC).
\n\nA Coordinated EU Approach to Global Health Security\nIn his remarks, Síkela emphasizes the shift in perception of health threats post-COVID-19, highlighting pandemic preparedness as a key security concern. He framed the EU’s Global Gateway strategy and the Team Europe approach, which pooled resources from EU institutions, member states, and financial bodies, as critical for multiplying health investments abroad. The Commissioner announced a €2 billion MAV+ initiative to develop vaccine and health product manufacturing capacity in Africa, aiming to increase local production from virtually zero to 60% by 2040, responding to African leaders' calls for strategic autonomy in healthcare.
\n\nBridging Public and Private Sectors with New Financial Tools and Reforms\nSíkela underscored the necessity of private sector participation to close the global infrastructure investment gap, citing the Human Development Accelerator fund (€750 million) co-managed with the Gates Foundation as a key financial instrument offering guarantees and flexible loans to de-risk investments along the vaccine value chain. Regulatory reforms and the operationalization of the African Medicines Agency are also highlighted to ease market access and boost regional integration. \n \n\nExpanding Strategy to Latin America and the Caribbean\nIn LAC, the EU aims to mobilize up to €45 billion in sustainable investments targeting local vaccine and health product production, with projects such as Colombia’s new vaccine facility and upgrades in Cuba. The strategy balances harmonizing regulatory frameworks and fostering scientific collaboration through initiatives like Horizon Europe.
\n\nPolitical Significance and Stakeholders\nThis approach reflects a push towards increasing EU influence in global health governance by strengthening partners’ industrial base and regulatory autonomy, showing a tilt toward greater EU intervention and collaboration in health sectors beyond its borders. The proposed blending of public funds with private investment introduces potential shifts in the risk and reward landscape for European and African pharmaceuticals industries, potentially expanding business opportunities but also imposing demands for compliance with new regulatory standards. National African and Latin American authorities may see enhanced institutional capacities, while EU regulatory bodies have a greater advisory and coordination role. For consumers, greater local production aims to improve vaccine availability and health security. However, the high investment and operational risks highlighted by Síkela might pose challenges for smaller private sector actors. Overall, the speech signals a concrete policy direction focused on scaling up regional manufacturing, regulatory reform, and public-private financing partnerships rather than only declarative commitments, showing an EU ambition to blend health security with economic development and global influence.
← Atlas › News › Development & Humanitarian Aid